aTen Therapeutics
An innovative biotechnology company based in Edinburgh, Scotland
We are developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Our technology has great potential to provide powerful new treatment options to extend and improve lives.
TENSINUMAB (ATN-E11)
Our lead candidate - a novel therapeutic human antibody that significantly inhibits tumour growth and prolongs survival in experimental models of cancer.
